164 related articles for article (PubMed ID: 10370787)
1. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
van Moorsel CJ; Kroep JR; Pinedo HM; Veerman G; Voorn DA; Postmus PE; Vermorken JB; van Groeningen CJ; van der Vijgh WJ; Peters GJ
Ann Oncol; 1999 Apr; 10(4):441-8. PubMed ID: 10370787
[TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
van Moorsel CJ; Pinedo HM; Smid K; Comijn EM; Voorn DA; Veerman G; Lakerveld B; Van der Vijgh WJ; Giaccone G; Postmus PE; Peters GJ
Eur J Cancer; 2000 Dec; 36(18):2420-9. PubMed ID: 11094319
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Rademaker-Lakhai JM; Crul M; Pluim D; Sparidans RW; Baas P; Beijnen JH; van Zandwijk N; Schellens JH
Anticancer Drugs; 2005 Oct; 16(9):1029-36. PubMed ID: 16162981
[TBL] [Abstract][Full Text] [Related]
5. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
Kroep JR; Giaccone G; Voorn DA; Smit EF; Beijnen JH; Rosing H; van Moorsel CJ; van Groeningen CJ; Postmus PE; Pinedo HM; Peters GJ
J Clin Oncol; 1999 Jul; 17(7):2190-7. PubMed ID: 10561275
[TBL] [Abstract][Full Text] [Related]
7. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-cisplatin: a schedule finding study.
Kroep JR; Peters GJ; van Moorsel CJ; Catik A; Vermorken JB; Pinedo HM; van Groeningen CJ
Ann Oncol; 1999 Dec; 10(12):1503-10. PubMed ID: 10643544
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
10. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer.
Fan Y; Lin NM; Ma SL; Luo LH; Fang L; Huang ZY; Yu HF; Wu FQ
Acta Pharmacol Sin; 2010 Jun; 31(6):746-52. PubMed ID: 20523345
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.
Caffo O; Fallani S; Marangon E; Nobili S; Cassetta MI; Murgia V; Sala F; Novelli A; Mini E; Zucchetti M; Galligioni E
Cancer Chemother Pharmacol; 2010 May; 65(6):1197-202. PubMed ID: 20140616
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
Sabbatini P; Aghajanian C; Leitao M; Venkatraman E; Anderson S; Dupont J; Dizon D; O'Flaherty C; Bloss J; Chi D; Spriggs D
Clin Cancer Res; 2004 May; 10(9):2962-7. PubMed ID: 15131031
[TBL] [Abstract][Full Text] [Related]
14. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Schultheis B; Kummer G; Zeth M; Brendel E; Xia C; Kornacker M; Strumberg D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):333-9. PubMed ID: 21735354
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Ceresa C; Giovannetti E; Voortman J; Laan AC; Honeywell R; Giaccone G; Peters GJ
Mol Cancer Ther; 2009 May; 8(5):1026-36. PubMed ID: 19383850
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Crul M; Schoemaker NE; Pluim D; Maliepaard M; Underberg RW; Schot M; Sparidans RW; Baas P; Beijnen JH; Van Zandwijk N; Schellens JH
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3526-33. PubMed ID: 14506138
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
Grunewald R; Kantarjian H; Keating MJ; Abbruzzese J; Tarassoff P; Plunkett W
Cancer Res; 1990 Nov; 50(21):6823-6. PubMed ID: 2208147
[TBL] [Abstract][Full Text] [Related]
19. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
[TBL] [Abstract][Full Text] [Related]
20. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Rajan A; Carter CA; Kelly RJ; Gutierrez M; Kummar S; Szabo E; Yancey MA; Ji J; Mannargudi B; Woo S; Spencer S; Figg WD; Giaccone G
Clin Cancer Res; 2012 Apr; 18(8):2344-51. PubMed ID: 22371451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
